LBIO (Longevity Biomedical) Cash Conversion Cycle: 0.00 (As of . 20)


What is Longevity Biomedical Cash Conversion Cycle?

Longevity Biomedical LBIO Cash Conversion Cycle is 0.00 as of . 20.

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Longevity Biomedical's Days Sales Outstanding for the six months ended in . 20 was .
Longevity Biomedical's Days Inventory for the six months ended in . 20 was .
Longevity Biomedical's Days Payable for the six months ended in . 20 was .
Therefore, Longevity Biomedical's Cash Conversion Cycle (CCC) for the six months ended in . 20 was 0.00.

Longevity Biomedical  (NAS:LBIO) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.

Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.

Longevity Biomedical Cash Conversion Cycle Related Terms

Longevity Biomedical Cash Conversion Cycle Historical Data

* Premium members only.

The historical data trend for Longevity Biomedical's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longevity Biomedical Cash Conversion Cycle Chart

Longevity Biomedical Annual Data
Trend
Cash Conversion Cycle

Longevity Biomedical Semi-Annual Data
Cash Conversion Cycle

LBIO vs : Cash Conversion Cycle Comparison

For the Biotechnology subindustry, Longevity Biomedical's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Longevity Biomedical Cash Conversion Cycle vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longevity Biomedical's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Longevity Biomedical's Cash Conversion Cycle falls into.


Longevity Biomedical Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Longevity Biomedical's Cash Conversion Cycle for the fiscal year that ended in . 20 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=+-
=0.00

Longevity Biomedical's Cash Conversion Cycle for the quarter that ended in . 20 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=+-
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash Conversion Cycle →
What does a Cash Conversion Cycle of 0.00 mean?
Longevity Biomedical (LBIO) has a Cash Conversion Cycle of 0.00 as of . 20. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Longevity Biomedical and its competitors.
Is Longevity Biomedical's Cash Conversion Cycle too high?
Longevity Biomedical's current Cash Conversion Cycle is 0.00.
How does Longevity Biomedical's Cash Conversion Cycle compare to ?
Longevity Biomedical's Cash Conversion Cycle of 0.00 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 104.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 104.03, based on 866 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Longevity Biomedical and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 104.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Longevity Biomedical's current Cash Conversion Cycle is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longevity Biomedical stock overvalued right now?
Longevity Biomedical (LBIO) has a current Cash Conversion Cycle of 0.00. The current Cash Conversion Cycle is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Longevity Biomedical (LBIO), the current Cash Conversion Cycle is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Longevity Biomedical Business Description

Comparable Companies
Address 12100 NE 195th street, Suite 150, Bothell, WA, USA, 98011
Longevity Biomedical Inc is a clinical-stage biomedical company. The company is focused on the advancement of new technologies across therapeutics, monitoring, and digital health that aim to restore tissue form and function to increase health span. Longevity is acquiring a differentiated therapeutic pipeline of late-stage clinical technologies across ophthalmology, cardiovascular disease, and soft tissue reconstruction and repair.